Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.

The inclusion criteria: * Age: ≥18 years old. * Ability to understand and provide informed consent: Participants must be able to understand the study and provide written informed consent fulfilling all relevant Institutional Review Board (IRB) or Independent Ethics Committee (IEC) guidelines. * Histologically confirmed prostate adenocarcinoma: A diagnosis confirmed through a pathology report or a clinical course consistent with the disease, as determined by a local pathologist, if a pathology specimen is unavailable. * ECOG performance status: 0 or 1 (fully active or restricted in strenuous activity but ambulatory). * Life expectancy: \>5 years. * Germline testing: Must have germline testing completed at the time of initial diagnosis and, if applicable, at recurrence. * No evidence of distant metastasis: No evidence of soft tissue disease metastasis (visceral or lymph nodes) on CT/MRI scan. * No active or organ-threatening autoimmune disease: Participants must not have an active or organ-threatening autoimmune disease. * High-risk or very high-risk prostate cancer: Based on 2024 NCCN guidelines: PSA \>20 ng/mL or Gleason Grade Group ≥4 or ≥cT3a. * Adequate hematologic and organ function: Defined by specific laboratory values (ANC, lymphocyte count, platelet count, hemoglobin, INR/aPTT, AST, ALT, alkaline phosphatase) obtained within 14 days prior to baseline, with specific exceptions stated in the protocol for participants with liver or bone metastases or those with known Gi…